Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Multiple sclerosis

On the road to the future: MS therapy today and tomorrow

    • Congress Reports
    • Neurology
    • RX
    • Studies
  • 3 minute read

Consistent research into multiple sclerosis and translation of findings into clinical practice has led to major advances in both understanding of the disease and therapy management in recent years. Exciting new drugs are in trials, and already established ones are being used more extensively and earlier than before with success.

Multiple sclerosis (MS) has many faces – making it a major challenge for everyone involved. Worldwide, about 2 million people suffer from MS, in Switzerland there are about 10,000. What causes the immune system to turn against its own body is not yet clearly understood. However, it is a fact that sclerosis develops during acute inflammatory activity. These lesions may slowly evolve during increasingly chronic inflammation to form leptomeningeal follicle-like aggregates. Here the danger exists, because outwardly inconspicuous, the progression of the disease often continues in secret. 60% of patients had progressive disability before escalation therapy was initiated, according to one study [1]. This speaks for the early use of highly active therapies, emphasized Prof. Ralf Gold, MD, Bochum (D). The risk of progressive clinical disease activity can thus be reduced by 74% [2].

Thrust-free does not necessarily mean progression-free

In the meantime, the course of the disease could be detected as a continuum, moving from the relapsing phase to the progressive form (Fig. 1) . The damage initially masked by remyelination and compensation comes to fruition over time through reduced repair and compensatory capacity. Vulnerability to comorbidities also increases over time. It has also been shown that axonal damage is greatest in early stages of disease [3]. The subject of recent investigations has been the role of B cells in disease progression. AK-independent B-cell function has been shown to play an important role in the pathogenesis of MS [4–6]. This is where antibodies attack. Primary progressive multiple sclerosis, previously considered untreatable, can now be treated with a CD20 antibody. The risk of disability progression was reduced by 25% in the pivotal study of ocrelizumab [7]. In addition, Bruton’s tyrosine kinase (BTK) plays an important role in cellular immune processes. This is to be addressed in the future with BTK inhibitors – studies are ongoing.

 

 

Fast onset of action for effective results

In relapsing-remitting MS, cladribine, an agent with antineoplastic and immunomodulatory activity, has been available for a good year. Oral therapy is characterized above all by a rapid onset of action, as the expert pointed out. An improvement in the thrust rate was already measurable after four weeks [8]. Overall, the time to first relapse was extended from 4.6 months on placebo to more than 13 months [9]. In addition, a significant effect on disability progression has been demonstrated [10]. These results were confirmed by recent evaluations: Already in the first examination section after one month MRI data showed a significant reduction of combined lesions – with increasing therapy effect over time [11].

Source: DGN 2020

 

Literature:

  1. Harding K, et al: JAMA Neurology 2019; DOI: 10.1001/jamaneurol.2018.4905.
  2. Freedman MS, et al: Mult Scler J Exp Transl Clin 2017; 3: 2055217317732802.
  3. Pfeifenbring, et al: Ann Neurol 2015; 77: 655-667.
  4. Bar-Or, et al: Ann Neurol 2010; 67: 452-461.
  5. Fraussen J, et al: Autoimmune Rev 2016; 15: 896-899.
  6. Jelcic I, et al: Cell 2018; 175: 85-100.
  7. Montalban X, et al: N Engl J Med 2017; 376(3): 209-220.
  8. Vemersch, et al.: ECTRIMS 2009 [P617]
  9. Comi G, et al: ECTRIMS 2009 [P469]
  10. Giovannoni G, et al: NEMJ 2010; 362: 416-426.
  11. De Stefano N, et al: ACTRIMS/ECTRIMS 2020. [P0382]

 

InFo NEUROLOGY & PSYCHIATRY 2020; 18(6): 22 (published 11/28/20, ahead of print).

Autoren
  • Leoni Burggraf
Publikation
  • InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
  • Multiple sclerosis
Previous Article
  • Orphan disease in oncology

Rare is also (cumulatively) common

  • Allergology and clinical immunology
  • Education
  • Infectiology
  • Oncology
  • Pharmaceutical medicine
  • RX
View Post
Next Article
  • Rare lung diseases

Pulmonary amyloidosis

  • CME continuing education
  • Education
  • Pneumology
  • RX
View Post
You May Also Like
View Post
  • 5 min
  • Long-term study with dementia patients

Ginkgo biloba extract significantly reduces the risk of progression

    • Education
    • General Internal Medicine
    • Geriatrics
    • Pharmaceutical medicine
    • Phytotherapy
    • Psychiatry and psychotherapy
    • RX
    • Studies
View Post
  • 3 min
  • Intestinal microbiome

Complex and fragile system of microorganisms

    • Education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Nutrition
    • RX
View Post
  • 3 min
  • Cancer prevention

Poorer prognosis for men who avoid prostate cancer screening

    • Congress Reports
    • Oncology
    • Prevention and health care
    • RX
    • Studies
    • Urology
View Post
  • 15 min
  • Diabetes mellitus

Treatment of comorbidities in older people

    • Cardiology
    • CME continuing education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Geriatrics
    • RX
View Post
  • 12 min
  • Liver steatosis with metabolic dysfunction

New nomenclature for non-alcoholic fatty liver disease

    • CME continuing education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • RX
    • Studies
View Post
  • 4 min
  • Type 2 diabetes: PAD and diabetic foot syndrome

Prevention is better than cure – don’t miss the risk foot

    • Cardiology
    • Congress Reports
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Geriatrics
    • Prevention and health care
    • RX
View Post
  • 2 min
  • Prostate cancer

High-resolution ultrasound could diagnose prostate cancer faster

    • Congress Reports
    • Oncology
    • RX
    • Studies
    • Urology
View Post
  • 9 min
  • Chronic lung diseases

Sarcopenia and malnutrition in the context of pneumological rehabilitation

    • CME continuing education
    • General Internal Medicine
    • Geriatrics
    • Nutrition
    • Pneumology
    • RX
    • Sports Medicine
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Treatment of comorbidities in older people
  • 2
    New nomenclature for non-alcoholic fatty liver disease
  • 3
    Rare malignancy from a dermatological perspective
  • 4
    Communication as the key to therapy adherence
  • 5
    Patience, knowledge and persistence in therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.